The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2022 | Updates on novel agents in development for aggressive B-cell lymphoma
In this video, Enrico Derenzini, MD, PhD, European Institute of Oncology, Milan, Italy, shares some insights into the landscape of novel therapies in development for aggressive B-cell lymphoma. Dr Derenzini first explains why many patients do not respond to first-line therapy, and how several novel agents, including antibody-drug conjugates (ADCs), bispecific antibodies, and CAR-T therapy, may benefit patients with relapsed/refractory (R/R) disease. To conclude, Dr Derenzini highlights the importance of combining immunotherapies in the future to improve outcomes for patients. This interview took place at the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
